ABSCIENCES (EPA:AB) | Finanzwire

PRESS RELEASE

published on 10/16/2025 at 20:57, 3 months 14 days ago

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science provides initial Phase 1 data for combination of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia. Promising results incl. 100% disease control rate and 100% response rate

AB Science AB8939 Phase 1 Data AML Venetoclax
BRIEF

published on 10/14/2025 at 08:41, 3 months 17 days ago

AB Science Reports Promising Initial Data from AML Study

Clinical Trial AML Treatment AB Science AB8939 Venetoclax
PRESS RELEASE

published on 10/14/2025 at 08:36, 3 months 17 days ago

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
AB Science releases positive initial data on combination treatment of AB8939 with Venetoclax for refractory or relapsed Acute Myeloid Leukemia (AML), showing promising results in patients with unfavorable genetic profiles. Virtual conference scheduled with renowned experts in AML

Virtual Conference AB Science AB8939 AML Venetoclax
BRIEF

published on 08/04/2025 at 08:03, 5 months 27 days ago

AB Science Completes EUR 2.55 Million Private Placement

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
PRESS RELEASE

published on 08/04/2025 at 07:58, 5 months 27 days ago

AB Science announces the successful completion of a 2.55 million euros private placement
AB Science successfully completes EUR 2.55 million private placement to fund clinical development. New shares issued with warrants attached

Private Placement Shareholders Clinical Development AB Science EUR 2.55 Million
BRIEF

published on 07/30/2025 at 07:50, 6 months 1 day ago

AB Science Advances in AML Study With New European Approvals

Regulatory Approval Market Potential AB8939 Venetoclax AML Study
PRESS RELEASE

published on 07/30/2025 at 07:45, 6 months 1 day ago

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining AB8939 with venetoclax for treatment of acute myeloid leukemia

Regulatory Approval AB Science AB8939 Venetoclax Phase I/II Study
BRIEF

published on 07/24/2025 at 08:01, 6 months 7 days ago

AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe

Phase 3 Trial ALS AB Science Masitinib European Approval
PRESS RELEASE

published on 07/24/2025 at 07:56, 6 months 7 days ago

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science receives approval from European countries to initiate Phase 3 study of masitinib in ALS following protocol validation by EMA and FDA

Phase 3 Study ALS AB Science Masitinib EMA
BRIEF

published on 07/08/2025 at 08:06, 6 months 23 days ago

AB Science Completes EUR 1.925 Million Private Placement

Private Placement Share Issuance Biotech Funding AB Science AB8939 Program

Published on 01/31/2026 at 03:15, 8 hours 38 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 9 hours 33 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 10 hours 13 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 11 hours 53 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 12 hours 53 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 9 hours 8 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 13 hours 53 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 15 hours 43 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 15 hours 43 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 15 hours 46 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 18 hours 8 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 1 day 3 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 17 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 18 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 18 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News